tert-Butyl 4-(4-iodophenyl)piperazine-1-carboxylate

Catalog No. :
ACGIUM736
CAS No. :
151978-66-4
Molecular Formula :
C15H21IN2O2
Molecular Weight :
388.25

IUPAC Name:tert-butyl 4-(4-iodophenyl)piperazine-1-carboxylate

tert-Butyl 4-(4-iodophenyl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g98%$88.00Login to see priceIn stockIn stock
25g98%$405.00Login to see priceIn stockIn stock
100g98%$1542.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(4-iodophenyl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-(4-iodophenyl)piperazine-1-carboxylate
MDL No.MFCD06200864
Molecular FormulaC15H21IN2O2
Molecular Weight388.25
SMILESCC(C)(C)OC(=O)N1CCN(CC1)C1=CC=C(I)C=C1
InChI KeyZOWJTZMYSLZILG-UHFFFAOYSA-N
SynonymCS-0206055 | DTXSID70383731 | 1-Piperazinecarboxylic acid, 4-(4-iodophenyl)-, 1,1-dimethylethyl ester | 1-Piperazinecarboxylicacid, 4-(4-iodophenyl)-, 1,1-dimethylethyl ester | TERT-BUTYL 4-(4-IODOPHENYL)TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE | EN300-737702
CAS No.151978-66-4
PubChem CID2795511

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H315-H319
Precautionary Statement(s)
P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362

Synthetic Route by SureRoute

1. ACGIUM736 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTRIQ032 route compound structure diagram
    ACTRIQ032352437-09-3 In Stock
  2. Then
  3. ACGIUM736 route product structure diagram
    ACGIUM736151978-66-4 In Stock
Inquiry

2. ACGIUM736 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGIUM736 route product structure diagram
    ACGIUM736151978-66-4 In Stock
Inquiry

Comments (0)